Diligence memo · auto-generated · as of July 2, 2026
Dome Therapeutics, LLC
Dome Therapeutics, LLC looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Dome Therapeutics, LLC operates in Biotechnology, based in PORTE VEDRA BEACH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Dome Therapeutics, LLC has raised $250K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $150K on 2020-11-17.
Most recent recorded round closed around 2024-01-15.
Valuation (modeled)modeled
Provath models Dome Therapeutics, LLC at approximately $614K (range $53K–$2.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.19× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 38 months.
Last raise 2.5 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 5% of Biotechnology peers (4293 compared).
Modeled value ranks above 1% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.